AMAG Pharmaceuticals Top Insiders

AMAG Pharmaceuticals employs about 440 people. The company is managed by 40 executives with a total tenure of roughly 339 years, averaging almost 8.0 years of service per executive, having 11.0 employees per reported executive. Examination of AMAG Pharmaceuticals' management performance can provide insight into the company performance.
William Heiden  CEO
CEO and Director
Gino Santini  Chairman
Chairman of the Board
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

AMAG Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (3.06) % which means that it has lost $3.06 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (62.88) %, meaning that it created substantial loss on money invested by shareholders. AMAG Pharmaceuticals' management efficiency ratios could be used to measure how well AMAG Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

AMAG Pharmaceuticals Workforce Comparison

AMAG Pharmaceuticals is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is presently estimated at about 50,181. AMAG Pharmaceuticals maintains roughly 440 in number of employees contributing less than 1% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of (77.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (13.88) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $13.88.

AMAG Pharmaceuticals Notable Stakeholders

An AMAG Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AMAG Pharmaceuticals often face trade-offs trying to please all of them. AMAG Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AMAG Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
William HeidenCEO and DirectorProfile
Gino SantiniChairman of the BoardProfile
Alan ButcherExecutive Vice President and Chief Business OfficerProfile
Oscar SanchezVice President - QualityProfile
Julie KropChief Medical Officer and Senior Vice President - Clinical Development and Regulatory AffairsProfile
Todd HornGeneral Manager - CBR and Senior Vice President - Consumer Marketing & Sales at AMAGProfile
Laura WilliamsSenior Vice President - Clinical DevelopmentProfile
Arpad SimonVice President - PharmacovigilanceProfile
Kathryn PayneVice President - External Affairs.Profile
Scott McMillanSenior Vice President - Quality and Technical OperationsProfile
Joseph VittiglioSenior Vice President General Counsel, SecretaryProfile
Nancy GriffithVice President - Scientific Communications And Medical OperationsProfile
Paul WilliamsSenior Vice President - Sales and Marketing, Lumara Health and Cord Blood RegistryProfile
Mark StantonVice President - Market Access and Corporate AccountsProfile
Edward MylesCFO, Senior Vice President - Finance, TreasurerProfile
Nicholas GrundExecutive Vice President Chief Commercial OfficerProfile
Aaron PeltaVice President - Business DevelopmentProfile
Elizabeth BolgianoSenior Vice President of Human ResourcesProfile
Tony CascianoSenior Vice President of Sales and Marketing - Hematology and Oncology businessProfile
Robert BrennerSenior Vice President - Medical AffairsProfile
Helen MiltonVice President - Regulatory AffairsProfile
Frank ThomasPres and COOProfile
Nathan McBrideCIO and Sr. VP of Innovation ArchitectsProfile
Edward JordanSr. VP of Sales and MarketingProfile
Melissa KlugSr. VP of Bus. Devel. and StrategyProfile
Cooper RussellIndependent DirectorProfile
Kathrine OBrienIndependent DirectorProfile
Davey ScoonIndependent DirectorProfile
John FallonDirectorProfile
Anne PhillipsIndependent DirectorProfile
Robert PerezIndependent DirectorProfile
Katie PayneExecutive Director, Investor Relations & Corporate CommunicationsProfile
James SulatIndependent DirectorProfile
Lesley CooperIndependent DirectorProfile
Brian KelleyIndependent DirectorProfile
Barbara DeptulaIndependent DirectorProfile
Lesley RussellIndependent DirectorProfile
Linda LennoxVP of Investor Relations and Corporate CommunicationsProfile
Tracy BernsChief Compliance OfficerProfile
Anthony CascianoChief Commercial OfficerProfile

AMAG Pharmaceuticals Workforce Analysis

Traditionally, organizations such as AMAG Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AMAG Pharmaceuticals within its industry.

AMAG Pharmaceuticals Manpower Efficiency

Return on AMAG Pharmaceuticals Manpower

Revenue Per Employee682.1K
Revenue Per Executive7.5M
Net Loss Per Employee526.4K
Net Loss Per Executive5.8M
Working Capital Per Employee819.9K
Working Capital Per Executive9M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the AMAG Pharmaceuticals information on this page should be used as a complementary analysis to other AMAG Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in AMAG Stock

If you are still planning to invest in AMAG Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AMAG Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Money Managers
Screen money managers from public funds and ETFs managed around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon